cheap here !
there is no reason they HAD to sell except they don't have much confideance in this drug. Will Not Buy.
Fly On The Wall After Hours 8:42 P.M.
May 16, 2013
08:42 EDT HALO Halozyme data favorable, says JMP Securities
JMP Securities was highly encouraged by data from a Phase I trial of Halozyme's PEGPH20 in pancreatic cancer, as the drug generated response rates that were significantly higher than competing drugs,according to the firm. JMP Securities raised its target on Halozyme to $12 from $10 and reiterates an Outperform rating on the shares
wow desperate short or wants in cheap.
fezzi your an idiot posting something from 2006 !!!!!!!!!!!!!!!!
"This sNDA approval of BASF as a supplier of Vascepa follows the recent sNDA approval to add Chemport, Inc. as a Vascepa API supplier and brings the number of approved Vascepa API suppliers to three. The BASF approval represents an additional step toward the goal of expanding our global supply chain tosupport expected Vascepa demand, diversify our supply base, and ensure cost-efficient supply. In addition, Amarin has plans for the submission of a fourth planned supplier in 2013.
Thank You Previous Poster-
Google to Verify
Lovaza has also been demonstrated to reduce VLDL-cholesterol and non-HDL-cholesterol, and increase HDL-cholesterol. But, it can raise LDL-cholesterol up to 45% Vascepa will undoubtedly become a major competitor for Lovaza. In clinicial trials, Vascepa was shown to lower triglycerides; while Lovaza also lowers the triglyceride concentration, Vascepa also lowers LDL-C; Lovaza does not. Lovaza was approved to treat people with very high triglyceride levels ( 500 mg/dl), Vascepa is also approved for this market; however the company has also demonstrated that the drug can impact levels in people with high triglyceride ( 200 mg/dl and